Cargando…

Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies

Prognosis of patients with cystic fibrosis (CF) varies extensively despite recent advances in targeted therapies that improve CF transmembrane conductance regulator (CFTR) function. Despite being a multi-organ disease, extensive lung tissue destruction remains the major cause of morbidity and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allan, Katelin M., Farrow, Nigel, Donnelley, Martin, Jaffe, Adam, Waters, Shafagh A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007963/ https://www.ncbi.nlm.nih.gov/pubmed/33796025 http://dx.doi.org/10.3389/fphar.2021.639475

Ejemplares similares

Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic
por: Donnelley, Martin, et al.
Publicado: (2018)

Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
por: Awatade, Nikhil T., et al.
Publicado: (2018)

Single-Dose Lentiviral Mediated Gene Therapy Recovers CFTR Function in Cystic Fibrosis Knockout Rats
por: Reyne, Nicole, et al.
Publicado: (2021)

Breaching the Delivery Barrier: Chemical and Physical Airway Epithelium Disruption Strategies for Enhancing Lentiviral-Mediated Gene Therapy
por: McCarron, Alexandra, et al.
Publicado: (2021)

Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology
por: Rout-Pitt, Nathan, et al.
Publicado: (2018)

Cystic fibrosis-related diabetes and lung disease: an update
por: Prentice, Bernadette J., et al.
Publicado: (2021)

Gene therapy for cystic fibrosis: Challenges and prospects
por: Sui, Hongshu, et al.
Publicado: (2022)

Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator
por: Villamizar, Olga, et al.
Publicado: (2019)

Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions
por: Fawcett, Laura K., et al.
Publicado: (2021)

Mesenchymal Stem Cell exosome delivered Zinc Finger Protein activation of cystic fibrosis transmembrane conductance regulator
por: Villamizar, Olga, et al.
Publicado: (2021)

Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis
por: Berical, Andrew, et al.
Publicado: (2019)

Comparing Cytology Brushes for Optimal Human Nasal Epithelial Cell Collection: Implications for Airway Disease Diagnosis and Research
por: Fawcett, Laura K., et al.
Publicado: (2023)

On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis
por: Ensinck, Marjolein, et al.
Publicado: (2021)

Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis
por: Esposito, Susanna, et al.
Publicado: (2019)

Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis
por: Perrem, Lucy, et al.
Publicado: (2020)

Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine
por: Pranke, Iwona, et al.
Publicado: (2019)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis
por: Noel, Sabrina, et al.
Publicado: (2012)

Airway disease phenotypes in animal models of cystic fibrosis
por: McCarron, Alexandra, et al.
Publicado: (2018)

Animal Models in the Pathophysiology of Cystic Fibrosis
por: Semaniakou, Anna, et al.
Publicado: (2019)

The Resolution Approach to Cystic Fibrosis Inflammation
por: Recchiuti, Antonio, et al.
Publicado: (2020)

Enhancing Cystic Fibrosis Immune Regulation
por: van Heeckeren, Anna M., et al.
Publicado: (2021)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

CFTR and Ca(2+) Signaling in Cystic Fibrosis
por: Antigny, Fabrice, et al.
Publicado: (2011)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Personalized or Precision Medicine? The Example of Cystic Fibrosis
por: Marson, Fernando A. L., et al.
Publicado: (2017)

Editorial: Emerging Therapeutic Approaches for Cystic Fibrosis
por: Lopes-Pacheco, Miquéias, et al.
Publicado: (2019)

Cystic Fibrosis Lung Disease in the Aging Population
por: Künzi, Lisa, et al.
Publicado: (2021)

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
por: Olivier, Margarete, et al.
Publicado: (2023)

Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis
por: Trend, Stephanie, et al.
Publicado: (2018)

Gene therapy for the treatment of cystic fibrosis
por: Burney, Tabinda J, et al.
Publicado: (2012)

Genetic Influences on Cystic Fibrosis Lung Disease Severity
por: Weiler, Colleen A., et al.
Publicado: (2013)

TMEM16A in Cystic Fibrosis: Activating or Inhibiting?
por: Kunzelmann, Karl, et al.
Publicado: (2019)

Emerging microRNA Therapeutic Approaches for Cystic Fibrosis
por: Bardin, Pauline, et al.
Publicado: (2018)

Mitochondrial Stress Responses and “Mito-Inflammation” in Cystic Fibrosis
por: Patergnani, Simone, et al.
Publicado: (2020)

Update on Calcium Signaling in Cystic Fibrosis Lung Disease
por: Rimessi, Alessandro, et al.
Publicado: (2021)

β-Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells
por: Lampronti, Ilaria, et al.
Publicado: (2017)

Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials
por: Wang, Yizi, et al.
Publicado: (2022)

Anion-Transport Mechanism of a Triazole-Bearing Derivative of Prodigiosine: A Candidate for Cystic Fibrosis Therapy
por: Cossu, Claudia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_acdh0bmta7ct1mtlnv623lp75g